Related Experiment Videos
Apoptosis by Par-4 in cancer and neurodegenerative diseases
Nadia El-Guendy1, Vivek M Rangnekar
1Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY 40536, USA.
Abstract:
Prostate apoptosis response-4 (par-4) is a pro-apoptotic gene identified in prostate cancer cells undergoing apoptosis. Par-4 protein, which contains a leucine zipper domain at the carboxy-terminus, functions as a transcriptional repressor in the nucleus. Par-4 selectively induces apoptosis in androgen-independent prostate cancer cells and Ras-transformed cells but not in androgen-dependent prostate cancer cells or normal cells. Cells that are resistant to apoptosis by Par-4 alone, however, are greatly sensitized by Par-4 to the action of other pro-apoptotic insults such as growth factor withdrawal, tumor necrosis factor, ionizing radiation, intracellular calcium elevation, or those involved in neurodegenerative diseases such as Alzheimer's, Parkinson's, Huntington's, and stroke. Apoptosis induction by Par-4 involves a complex mechanism that requires activation of the Fas death receptor signaling pathway and coparallel inhibition of cell survival NF-kappaB transcription activity. The unique ability of Par-4 to induce apoptosis in cancer cells but not normal cells and the ability of Par-4 antisense or dominant-negative mutant to abrogate apoptosis in neurodegenerative disease paradigms makes it an appealing candidate for molecular therapy of cancer and neuronal diseases.
Insights
Prostate apoptosis response-4 (PAR-4) selectively induces cancer cell death but not in normal cells. PAR-4 sensitizes resistant cells to apoptosis, offering potential for cancer and neurodegenerative disease therapies.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Prostate apoptosis response-4 (PAR-4) is a pro-apoptotic gene crucial in cancer cell apoptosis.
- PAR-4 protein acts as a transcriptional repressor, featuring a carboxy-terminal leucine zipper domain.
- It selectively induces apoptosis in specific cancer cell types, sparing normal cells.
Purpose of the Study:
- To investigate the selective apoptotic role of PAR-4 in cancer and its therapeutic potential.
- To explore PAR-4's mechanism in sensitizing cells to various apoptotic stimuli.
- To evaluate PAR-4 as a therapeutic target for cancer and neurodegenerative diseases.
Main Methods:
- Analysis of PAR-4's pro-apoptotic activity in different cell lines (androgen-dependent/independent prostate cancer, Ras-transformed, normal cells).
- Assessment of PAR-4's sensitization effect on apoptosis induced by growth factor withdrawal, TNF, ionizing radiation, and calcium elevation.
- Investigation of PAR-4's role in neurodegenerative disease models (Alzheimer's, Parkinson's, Huntington's, stroke).
- Examination of the molecular mechanisms involving Fas death receptor pathway and NF-kappaB inhibition.
Main Results:
- PAR-4 selectively induces apoptosis in androgen-independent prostate cancer cells and Ras-transformed cells.
- PAR-4 sensitizes cells resistant to apoptosis to various insults, including those relevant to neurodegenerative diseases.
- Apoptosis induction by PAR-4 involves Fas pathway activation and NF-kappaB inhibition.
Conclusions:
- PAR-4 exhibits selective apoptosis-inducing properties in cancer cells, not normal cells.
- PAR-4 enhances apoptosis sensitivity in resistant cells, highlighting its therapeutic potential.
- PAR-4 is a promising candidate for molecular therapies targeting cancer and neurodegenerative conditions.